ZUO LI YAO YE(SZ:300181)2025-09-06 14:30Group 1: OTC Strategy and Performance - The company has adjusted its OTC strategy by merging the OTC sales department with the OTC marketing department to form the OTC division, enhancing overall marketing and sales efficiency [1] - A new large packaging product was launched, and strategic partnerships with leading chains were formed, contributing to significant sales growth in the outpatient channel in the first half of the year [1] Group 2: Future Growth Potential of Wuling Capsule - The company aims to develop Wuling Capsule into a product with a market scale exceeding 2 billion, leveraging the high sleep disturbance rate of 48.5% among the population aged 18 and above [2] - Currently, OTC sales revenue from Wuling Capsule accounts for approximately 10%, with plans to increase this to over 20% through enhanced C-end strategies [2] - Wuling Capsule is currently available in about 15,000 hospitals, with significant room for expansion given the total number of medical institutions in China exceeds one million [2] Group 3: Investment in Lingyi Biotech - Lingyi Biotech focuses on innovative drug development for single-gene hereditary diseases, with a recent investment of 20 million yuan made by the company in April 2025 [3] - The collaboration is expected to enhance the company's capabilities in the neurological field, particularly through the LY-N001 pipeline targeting Parkinson's disease [3] - Future investments in Lingyi Biotech will depend on the progress and breakthroughs of the LY-N001 pipeline [3]